QT
QTRX.US Quanterix Corp
- Market cap
- USD 136M
- P/E
- -
- P/B
- 0.63x
- ROE
- -53.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is QTRX.US undervalued?
Graham numberThe Graham number of Quanterix Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Quanterix Corp fundamental analysis
No fundamental analysis for Quanterix Corp yet.
Quanterix Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Quanterix Corp
Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include as…
Full company profileQuanterix Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Quanterix Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 17.6M | 22.9M | 37.6M | 56.7M | 86.4M | 111M | 106M | 121M | 135M | 139M | 139M |
| Gross Profit | 7.75M | 9.99M | 18.0M | 26.8M | 48.2M | 61.7M | 45.4M | 73.0M | 81.1M | 64.7M | 55.7M |
| Operating Income | -21.7M | -26.0M | -31.6M | -41.6M | -31.6M | -58.6M | -104M | -46.0M | -52.6M | -110M | -125M |
| EBITDA | -21.4M | -25.6M | -30.2M | -38.6M | -27.3M | -53.7M | -67.2M | -36.4M | -29.7M | -93.3M | -99.3M |
| Net Income | -23.2M | -27.0M | -31.0M | -40.8M | -31.5M | -57.7M | -99.6M | -28.4M | -38.5M | -107M | -117M |
| EPS | -1.43 | -1.24 | -1.39 | -1.63 | -1.07 | -1.60 | -2.69 | -0.75 | -1.00 | -2.51 | -2.48 |
| Balance Sheet | |||||||||||
| Total Assets | 37.1M | 91.8M | 67.6M | 170M | 271M | 507M | 434M | 429M | 407M | 419M | 300M |
| Total Liabilities | 23.6M | 25.9M | 26.1M | 41.3M | 64.9M | 65.6M | 75.7M | 78.6M | 76.5M | 123M | 81.1M |
| Shareholders' Equity | 13.5M | 65.9M | 41.6M | 129M | 206M | 441M | 358M | 350M | 330M | 296M | 219M |
| Cash & Short-term Investments | 29.7M | 79.7M | 45.4M | 109M | 182M | 396M | 339M | 321M | 289M | 118M | 77.4M |
| Total Debt | 13.0M | 9.38M | 8.09M | 7.66M | 30.8M | 21.9M | 44.1M | 41.5M | 37.4M | 37.2M | 31.4M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -17.7M | -22.1M | -28.7M | -26.2M | -23.4M | -47.9M | -48.3M | -18.9M | -35.2M | -77.2M | -42.3M |
| Capital Expenditure | 526K | 1.13M | 1.52M | 10.8M | 3.93M | 13.6M | 11.7M | 3.79M | 3.37M | 2.61M | 344K |
| Free Cash Flow | -18.3M | -23.2M | -30.2M | -37.0M | -27.3M | -61.5M | -60.0M | -22.7M | -38.5M | -79.8M | -52.9M |
| Ratios | |||||||||||
| ROE | -172.0% | -41.0% | -74.7% | -31.7% | -15.3% | -13.1% | -27.8% | -8.1% | -11.7% | -36.2% | -53.5% |
| ROA | -62.4% | -29.4% | -45.9% | -24.0% | -11.6% | -11.4% | -23.0% | -6.6% | -9.5% | -25.6% | -39.1% |
| Net Profit Margin | -131.8% | -118.1% | -82.5% | -71.9% | -36.5% | -52.2% | -94.4% | -23.4% | -28.4% | -77.3% | -84.4% |
| Debt to Equity | 0.97x | 0.14x | 0.19x | 0.06x | 0.15x | 0.05x | 0.12x | 0.12x | 0.11x | 0.13x | 0.14x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Quanterix Corp dividends
Quanterix Corp has not paid dividends in the last 9 fiscal years.
Who owns Quanterix Corp
- Insiders 6.35%
- Institutions 70.72%
- Public & others 22.93%
- Shares outstanding 47.5M
- Free float 38.2M
Top funds holding QTRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| First Eagle Small Cap Opportunity I | 1.92M | 4.04% | -10.16% | Sep 2026 |
| Strategic Advisers U.S. Total Stock | 1.44M | 3.04% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.25M | 2.64% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.10M | 2.32% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 485K | 1.02% | +4.34% | Aug 2026 |
| iShares Russell 2000 Value ETF | 392K | 0.83% | 0.00% | Oct 2026 |
| iShares Biotechnology ETF | 309K | 0.65% | -0.19% | Oct 2026 |
| Fidelity Enhanced Small Cap Core ETF | 248K | 0.52% | +0.27% | Oct 2026 |
| Vanguard Russell 2000 ETF | 247K | 0.52% | +0.60% | Sep 2026 |
| Fidelity Extended Market Index | 210K | 0.44% | -0.38% | Sep 2026 |
| First Eagle US Small Cap Opp I-UC | 182K | 0.38% | -7.10% | Sep 2026 |
| DFA US Micro Cap I | 159K | 0.34% | 0.00% | Sep 2026 |
| iShares Micro-Cap ETF | 130K | 0.27% | 0.00% | Oct 2026 |
| CREF Total Global Stock Account R3 | 125K | 0.26% | -4.95% | Sep 2026 |
| Vanguard Health Care ETF | 120K | 0.25% | +0.78% | Sep 2026 |
| Schwab Small Cap Index | 104K | 0.22% | 0.00% | Sep 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 93.1K | 0.20% | 0.00% | Oct 2026 |
| Vanguard Strategic Small-Cap Equity Inv | 90.7K | 0.19% | 0.00% | Sep 2026 |
| Avantis US Small Cap Equity ETF | 89.5K | 0.19% | 0.00% | Oct 2026 |
| AQR Small Cap Multi-Style I | 82.2K | 0.17% | 0.00% | Jun 2026 |
Top institutions holding QTRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Arnhold & S. Bleichroeder Advisers, LLC | 5.51M | 11.60% | +323.54% | Jun 2026 |
| BlackRock Inc | 3.64M | 7.66% | +10.92% | Jun 2026 |
| Blue Water Life Science Advisors, LLC | 3.47M | 7.32% | +62.18% | Jun 2026 |
| Portolan Capital Management, LLC | 1.90M | 4.00% | -35.53% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.80M | 3.79% | +0.90% | Jun 2026 |
| Lionhunter Capital Management, LLC | 1.50M | 3.16% | 0.00% | Jun 2026 |
| AQR Capital Management LLC | 1.34M | 2.83% | +1,496.31% | Jun 2026 |
| Geode Capital Management, LLC | 1.13M | 2.38% | +13.73% | Jun 2026 |
| Ameriprise Financial Inc | 987K | 2.08% | -72.13% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 974K | 2.05% | +56.48% | Jun 2026 |
| State Street Corp | 932K | 1.96% | +3.79% | Jun 2026 |
| Tikvah Management LLC | 572K | 1.20% | -0.01% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 490K | 1.03% | -15.09% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 488K | 1.03% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 448K | 0.94% | -26.35% | Jun 2026 |
| Jane Street Group LLC | 419K | 0.88% | +169.22% | Jun 2026 |
| GSA Capital Partners LLP | 410K | 0.86% | +329.46% | Jun 2026 |
| Tudor Investment Corp Et AL | 400K | 0.84% | +26.71% | Jun 2026 |
| Northern Trust Corp | 337K | 0.71% | -3.56% | Jun 2026 |
| Charles Schwab Investment Management Inc | 311K | 0.65% | -10.18% | Jun 2026 |
Quanterix Corp company profile
- Company name
- Quanterix Corp
- Ticker
- QTRX.US
- Exchange
- USA Stocks
- Listed since
- Dec 7, 2017
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 450
- Fiscal year end
- December
- Address
- Building 1, Billerica, MA, United States, 01821
- Phone
- 617 301 9400
- Website
- quanterix.com
About Quanterix Corp
Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research and clinical laboratory testing services, including research and clinical trial testing, and lucent diagnostic services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and sales force and distributors. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Quanterix Corp management
10- Mr. William P. DonnellyExecutive Chair · born 1962
- Dr. David R. Walt Ph.D.Co-Founder & Chairman of Scientific Advisory Board · born 1953
- Mr. Everett V. CunninghamPresident, CEO & Director · born 1966
- Mr. Jason FaesslerCFO & Treasurer
- Mr. Anthony CatalanoChief Operating Officer
- Dr. Michael Miller Ph.D.Chief Technology & Products Officer · born 1964
- Joshua YoungHead of Investor Relations
- Mr. Daniel S. Char J.D.Chief Legal Officer & Corporate Secretary · born 1961
- Ms. Erica BellChief People Officer · born 1973
- Mr. Naren BhatChief Strategy Officer